vascular cognitive impairment no dementia
Conditions
Interventions
Experimental group :On the basis of routine treatment and nursing, combined with EEG biofeedback adjuvant therapy, once a day, 30 minutes each time, 5 times a week, a total of 10 times (intervention f
Control group:Routine treatment includes: controlling blood pressure, regulating blood sugar, regulating lipid metabolism, nourishing nerves, and improving circulation, while administering drugs that
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
All
Age
50 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1)The patient has good medical compliance and has informed consent to participate in this clinical study; (2) No contraindications for EEG biofeedback therapy; (3) Imaging findings indicate vascular origin, including lacunar infarction, cortical or subcortical stroke or hemorrhage, and ischemic changes in white matter, with evidence of sustained exacerbation or fluctuating progression, focal neurological signs, or insufficient cerebral perfusion; (4) Vascular cognitive impairment appears alone or coexists with other forms of dementia;
Exclusion criteria
Exclusion criteria: (1) Patients with severe primary diseases such as heart, liver, and kidney; (2) Individuals with severe mental illness; (3) Epilepsy, encephalitis, and traumatic brain injury patients; (4) Patients with scalp infection (unable to install electrodes due to scalp infection); (5) Patients with organic brain lesions (such as brain tumors, cerebral hemorrhage, etc.); (6) Individuals who may experience cognitive impairment due to alcohol dependence or drug addiction; (7) Psychiatric patients who are uncooperative or agitated; (8) Individuals who are allergic to contact parts of test equipment; (9) Participate in other clinical studies within 3 months; (10) Those who are unable or unwilling to provide informed consent or unable to comply with experimental requirements; Those who use similar medical devices within two weeks; Individuals who have adjusted their use of puzzle drugs within 2 weeks; Those who are not suitable to participate in this clinical trial due to other reasons; (11) Unconscious, especially for unconscious patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mini Mental State Scale;Event related potential P300;Pittsburgh Sleep Quality Index Scale;Hamilton Depression Rating Scale ;Hamilton Anxiety Scale;Daily living ability scale; | — |
Countries
China
Contacts
Public ContactZhang Li
Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed